19 terminated, 9 active not recruiting, 9 recruiting, 8 completed. 46 Phase 1, 33 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 46 | Terminated 19, Active not recruiting 9, Recruiting 9, Completed 8, Not yet recruiting 1 |
| Phase 2 | 33 | Terminated 18, Active not recruiting 6, Completed 6, Recruiting 3 |
Follow Genmab: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| A Phase 1 Trial of GEN1119 in Participants With Solid Tumors GEN1119 - Solid Tumours | Phase 1 | Recruiting | Genmab | 112 | 2026-08-13 | 2026-10-06 |
| A Study of GEN1106 in Participants With Solid Tumors GEN1106 - Solid Tumors, Urothelial Carcinoma | Phase 1 | Recruiting | Genmab | 103 | 2026-04-14 | 2026-10-06 |
| Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors GEN1079 - Advanced Solid Tumors | Phase 1 | Recruiting | Genmab | 121 | 2026-04-07 | 2026-09-09 |
| First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) GEN3018 - R/R AML, R/R HR-MDS | Phase 1 | Recruiting | Genmab | 78 | 2026-02-16 | 2026-10-27 |
| A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer BNT314, Pumitamig, SoC chemotherapy treatment 1 - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 482 | 2025-07-18 | 2026-07-01 |
| Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder | Phase 1 | Recruiting | Timothy Voorhees | 26 | 2025-06-16 | 2026-09-24 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors GEN1078 - Malignant Solid Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 3 | 2025-01-29 | 2026-01-30 |
| Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin - Non-Hodgkin Lymphoma, Cytokine Release Syndrome | Phase 1 | Recruiting | Taylor Brooks | 20 | 2025-01-14 | 2026-06-25 |
| A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors GEN1286 - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 23 | 2024-11-13 | 2026-07-13 |
| Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors GEN1057, Premedication - Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors | Phase 1 | Terminated | Genmab | 23 | 2024-08-28 | 2026-10-07 |
| Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy GEN1055, Pembrolizumab, Standard Chemotherapy - Malignant Solid Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 21 | 2024-05-14 | 2026-08-11 |
| PRO1107 in Patients With Advanced Solid Tumors GEN1107 - Endometrial Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Genmab | 33 | 2024-01-03 | 2026-10-29 |
| Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors BNT314 - Advanced Malignant Solid Tumor | Phase 1 | Active not recruiting | BioNTech SE | 41 | 2023-11-30 | 2026-09-15 |
| A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors GEN1042, Pembrolizumab, Cisplatin - Malignant Solid Tumor | Phase 1 | Active not recruiting | Genmab | 8 | 2023-11-24 | 2026-10-06 |
| A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma GEN3017 - Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 9 | 2023-09-21 | 2025-09-25 |
| Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) GEN1160 - Renal Cell Carcinoma, Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Terminated | Genmab | 42 | 2023-03-15 | 2026-03-04 |
| A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors GEN1042, Pembrolizumab, Radiotherapy - Non-CNS Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 13 | 2023-03-08 | 2026-08-12 |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Rina-S, Carboplatin, Bevacizumab - High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Genmab | 952 | 2022-12-07 | 2026-10-07 |
Showing 20 of 46. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7) · Lymphoma, Large B-Cell, Diffuse (7) · Endometrial Neoplasms (6) · Ovarian Neoplasms (6) · Uterine Cervical Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (5) · Colorectal Neoplasms (4) · Head and Neck Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Non-Hodgkin (4) · Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Esophageal Neoplasms (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3)
pembrolizumab (8) · Carboplatin (5) · Cyclophosphamide (5) · Doxorubicin (5) · Prednisone (5) · Rituximab (5) · zalutumumab (5) · Gemcitabine (4) · Lenalidomide (4) · Vincristine (4) · tisotumab vedotin (4) · Bevacizumab (3) · Cisplatin (3) · Magnetic Resonance Spectroscopy (3) · Oxaliplatin (3)
United States (32) · Spain (24) · Denmark (16) · Belgium (14) · United Kingdom (13) · France (11) · Japan (11) · Italy (9) · Netherlands (9) · Australia (6) · Czechia (6) · Sweden (6) · Germany (5) · Israel (5) · Poland (5)
Johann de Bono, Professor (2) · Hassan Aladdin, ICTM (1) · Ignace Vergote, Professor (1) · Jean-Pascal Machiels, MD, PhD (1) · Keiichi Fujiwara, Professor (1) · Roberto Oliveri, MD (1) · Ruth Plummer, Professor (1) · Sven De Vos (1) · Taylor Brooks, MD (1) · Timothy J Voorhees, MD (1) · Vincent Gregoire, MD professor (1)
PMID 37496366, PMID 41044356, PMID 42411504, PMID 42541678, PMID 17602769, PMID 30745090, PMID 31796521, PMID 34508654, PMID 35176764, PMID 35633184, PMID 35688554, PMID 36548927, PMID 37651655, PMID 38151388, PMID 38889737, PMID 39322711, PMID 39792928, PMID 40347227, PMID 40472301, PMID 40632620, PMID 40920572, PMID 41380698, PMID 41784015, PMID 42000372, PMID 42431612, PMID 42622258, PMID 42660129
2023 (10), 2025 (4), 2017 (3), 2018 (2), 2019 (2), 2016 (1), R01CA308586 (1)